A newly developed theory provides a fresh perspective, explaining the disease through the lens of brain plasticity and cholesterol transport. Published in the Annual Review of Biochemistry, this theory not only offers a novel explanation of AD but also suggests a potential treatment strategy.

Brain Plasticity: A Two-Stage Process

The brain’s ability to adapt—its plasticity—relies on structural and biochemical changes in neurons. Plasticity consists of two distinct stages:

1. Destabilization: The brain enters a flexible state, allowing new learning and adaptations.
2. Stabilization: The brain consolidates changes, strengthening connections and reinforcing memory.

Cholesterol plays a key role in transitioning between these stages. It ensures the stabilization phase is properly executed, allowing the brain to retain new experiences.

The Cholesterol Connection in AD

Neurons require cholesterol for plasticity but are nearly incapable of producing it themselves. Instead, cholesterol must be transported from astrocytes, a type of glial cell. In AD, this transfer process is impaired, leading to a breakdown in plasticity. As a result, neurons fail to properly stabilize new experiences, contributing to memory loss and cognitive decline.

This theory is supported by strong genetic evidence. The APOE gene, which has three forms (APOE2, APOE3, and APOE4), plays a critical role in cholesterol transport. People with the APOE4 variant have a significantly higher risk of developing AD, while those with APOE2 are largely protected. This correlation reinforces the idea that disrupted cholesterol transport is a fundamental cause of the disease.

Rethinking Amyloid Beta

The prevailing amyloid beta hypothesis argues that AD results from toxic amyloid beta buildup. However, in this new model, amyloid beta serves a physiological role in clearing cellular debris from plasticity processes. Its overproduction in AD is not the primary cause but a secondary effect of impaired cholesterol transport. When cholesterol supply is disrupted, neurons fail to regulate amyloid beta properly, leading to excessive clearance of neuronal structures and memory loss.

A Potential Treatment Pathway

If AD results from inadequate cholesterol delivery, then restoring proper cholesterol transport could improve brain function. While this theory does not fully reverse the root cause of AD, it offers a targeted approach to strengthen cholesterol pathways and mitigate cognitive decline. A pharmaceutical intervention could enhance cholesterol movement between astrocytes and neurons, potentially leading to better outcomes than current treatments.

While some experimental work has explored cholesterol’s role in AD, more research is needed. Pharmaceutical companies could develop a targeted drug based on this theory, which might prove superior to existing therapies. The main challenge lies in delivering the drug to the brain,